Cargando…
Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
BACKGROUND: Evidence on factors associated with guideline-directed secondary prevention medication (GDPM) after percutaneous coronary intervention (PCI) and its effect on the prognosis of patients with coronary artery disease (CAD) is lacking in China. AIMS: To ascertain predictors of GDPM in real-w...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ubiquity Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719473/ https://www.ncbi.nlm.nih.gov/pubmed/35141130 http://dx.doi.org/10.5334/gh.812 |
_version_ | 1784624942796505088 |
---|---|
author | Li, Tianyu Tang, Xiaofang Song, Ying Yao, Yi Zhao, Xueyan Gao, Zhan Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing |
author_facet | Li, Tianyu Tang, Xiaofang Song, Ying Yao, Yi Zhao, Xueyan Gao, Zhan Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing |
author_sort | Li, Tianyu |
collection | PubMed |
description | BACKGROUND: Evidence on factors associated with guideline-directed secondary prevention medication (GDPM) after percutaneous coronary intervention (PCI) and its effect on the prognosis of patients with coronary artery disease (CAD) is lacking in China. AIMS: To ascertain predictors of GDPM in real-world clinical practice and to assess the effect of GDPM on clinical outcomes. DESIGN: A retrospective cohort study. METHODS: Consecutive patients admitted to Fuwai Hospital between January 2013 and December 2013 were recruited. GDPM comprised aspirin, clopidogrel, statins, β-blockers, and angiotensin-converting enzyme inhibitors/angiotensin Ⅱ receptor blockers. The primary outcome was five-year major adverse cardiovascular event (MACE) (cardiac death, myocardial infarction [MI] and unplanned revascularization). Multivariable logistic regression was used to identify predictors of prescribing GDPM. Multivariable Cox regression was used to examine the relationship between GDPM and clinical outcomes. RESULTS: 10,067 patients were followed up for a median of 5.0 years (interquartile range: 4.3–5.2), 45.1% were prescribed with GDPM. Presenting with ST-segment elevation MI (adjusted OR = 3.252 [2.832–3.736]), prior MI (adjusted OR = 2.174 [1.948–2.425]), more stents implanted (adjusted OR = 1.063 [1.022–1.106]), overweight (adjusted OR = 1.136 [1.038–1.243]), obesity (adjusted OR = 1.274 [1.100–1.476]), diabetes (adjusted OR = 1.225 [1.115–1.344]), and hypertension (adjusted OR = 3.556 [3.196–3.956]) predicted the prescription of GDPM. Advanced age (adjusted OR = 0.556 [0.379–0.816]) was associated with lower prescription rate of GDPM. Patients with GDPM had lower rate of 5-year MACE (adjusted HR = 0.889 [0.808–0.978]) relative to those without GDPM. CONCLUSIONS: Despite the benefit of GDPM in improving the prognosis of CAD patients undergoing PCI, gaps still exist in GDPM prescription in real-world clinical practice. Our study determined target populations for physicians to strive to promote the application of GDPM. |
format | Online Article Text |
id | pubmed-8719473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ubiquity Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-87194732022-02-08 Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Li, Tianyu Tang, Xiaofang Song, Ying Yao, Yi Zhao, Xueyan Gao, Zhan Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing Glob Heart Original Research BACKGROUND: Evidence on factors associated with guideline-directed secondary prevention medication (GDPM) after percutaneous coronary intervention (PCI) and its effect on the prognosis of patients with coronary artery disease (CAD) is lacking in China. AIMS: To ascertain predictors of GDPM in real-world clinical practice and to assess the effect of GDPM on clinical outcomes. DESIGN: A retrospective cohort study. METHODS: Consecutive patients admitted to Fuwai Hospital between January 2013 and December 2013 were recruited. GDPM comprised aspirin, clopidogrel, statins, β-blockers, and angiotensin-converting enzyme inhibitors/angiotensin Ⅱ receptor blockers. The primary outcome was five-year major adverse cardiovascular event (MACE) (cardiac death, myocardial infarction [MI] and unplanned revascularization). Multivariable logistic regression was used to identify predictors of prescribing GDPM. Multivariable Cox regression was used to examine the relationship between GDPM and clinical outcomes. RESULTS: 10,067 patients were followed up for a median of 5.0 years (interquartile range: 4.3–5.2), 45.1% were prescribed with GDPM. Presenting with ST-segment elevation MI (adjusted OR = 3.252 [2.832–3.736]), prior MI (adjusted OR = 2.174 [1.948–2.425]), more stents implanted (adjusted OR = 1.063 [1.022–1.106]), overweight (adjusted OR = 1.136 [1.038–1.243]), obesity (adjusted OR = 1.274 [1.100–1.476]), diabetes (adjusted OR = 1.225 [1.115–1.344]), and hypertension (adjusted OR = 3.556 [3.196–3.956]) predicted the prescription of GDPM. Advanced age (adjusted OR = 0.556 [0.379–0.816]) was associated with lower prescription rate of GDPM. Patients with GDPM had lower rate of 5-year MACE (adjusted HR = 0.889 [0.808–0.978]) relative to those without GDPM. CONCLUSIONS: Despite the benefit of GDPM in improving the prognosis of CAD patients undergoing PCI, gaps still exist in GDPM prescription in real-world clinical practice. Our study determined target populations for physicians to strive to promote the application of GDPM. Ubiquity Press 2021-12-27 /pmc/articles/PMC8719473/ /pubmed/35141130 http://dx.doi.org/10.5334/gh.812 Text en Copyright: © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Li, Tianyu Tang, Xiaofang Song, Ying Yao, Yi Zhao, Xueyan Gao, Zhan Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention |
title | Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention |
title_full | Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention |
title_fullStr | Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention |
title_full_unstemmed | Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention |
title_short | Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention |
title_sort | predictors and outcomes of secondary prevention medication in patients with coronary artery disease undergoing percutaneous coronary intervention |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719473/ https://www.ncbi.nlm.nih.gov/pubmed/35141130 http://dx.doi.org/10.5334/gh.812 |
work_keys_str_mv | AT litianyu predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT tangxiaofang predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT songying predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT yaoyi predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT zhaoxueyan predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT gaozhan predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT yangyuejin predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT gaorunlin predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT xubo predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention AT yuanjinqing predictorsandoutcomesofsecondarypreventionmedicationinpatientswithcoronaryarterydiseaseundergoingpercutaneouscoronaryintervention |